Finoriq research workspace
BioNexus Gene Lab Corp (BGLC) SEC Filings & Filing Highlights
BioNexus Gene Lab Corp operates through three segments: Trading of Industrial Chemicals. Review BGLC SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
- Company
- BioNexus Gene Lab Corp (BGLC)
- Ticker
- BGLC
- Market Cap
- $4M
- Latest Price
- $1.67
- Industry
- Medical Devices
BioNexus Gene Lab Corp (BGLC) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BioNexus Gene Lab Corp (BGLC).
| Event | Form | Date |
|---|---|---|
| BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade...BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development | 8-K8.01 | 2026-06-05 |
| BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Office...BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Com... | 8-K8.01 | 2026-03-17 |
| BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Office...BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Com... | 8-K7.01 | 2026-03-17 |
| BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as...BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman | 8-K8.01 | 2026-02-23 |
| BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge...BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Mu... | 8-K8.01 | 2026-02-03 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.